Source: Manufacturing Chemist
Beximco Pharmaceuticals, the generic pharmaceutical products and API supplier, has signed a commercial agreement for distribution of certain products of Mylan in Bangladesh.
Under the terms of the agreement, Beximco Pharma will receive the exclusive rights to launch Mylan’s portfolio of key monoclonal antibodies to treat different types of cancers, rheumatoid arthritis, Crohn’s disease, ulcerative colitis and other medical conditions.
The first product to be launched, in Q1 2020, will be Ogivri, a breast cancer drug which is biosimilar to blockbuster drug Herceptin from Roche with global sales in excess of $7 billion in 2018. Ogivri is approved by the US FDA and has also received marketing authorisation from the EMA.
Nazmul Hassan, Managing Director of Beximco Pharmaceuticals, said: “We are incredibly excited to announce this commercial agreement with Mylan, the first of its kind in Bangladesh.”
Hassan continued to say that with one of the largest and most diverse portfolios of biosimilars approved in more than 80 countries, Mylan is the ideal partner for Beximco Pharma as the company enter the key therapeutic areas covered by biosimilar products.
“This unique partnership, which combines world-class product development, marketing and regulatory expertise, will introduce a portfolio of biologics, in particular, target-specific high-value monoclonal antibodies, in Bangladesh,” explained Hassan.
Commenting on the launch, Rakesh Bamzai, President of India and Emerging Markets at Mylan said: “The growing incidence of breast cancer is a major public health concern among women in Developing Markets. As a global leader in the development of complex products, including biosimilar medicines, Mylan, through its commercial agreement with Beximco Pharmaceuticals, is pleased to make Trastuzumab accessible to patients in Bangladesh.”